Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) price on current trading day, rose 4.31% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $49.38.
A look at the stock’s price movement, the close in the last trading session was $47.34, moving within a range at $47.265 and $49.47. The beta value (5-Year monthly) was 0.581. Turning to its 52-week performance, $60.37 and $37.02 were the 52-week high and 52-week low respectively. Overall, RARE moved -2.26% over the past month.
Ultragenyx Pharmaceutical Inc’s market cap currently stands at around $4.76 billion, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 146.85M for the company’s revenue for the quarter, with a low and high estimate of 138.1M and 158.36M respectively. The average forecast suggests up to a 15.27% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 542.36M, representing a 24.90% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RARE is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
16 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 14 recommend RARE as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RARE’s current price about 4.29% and -3.74% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 53.09, while 7-day volatility ratio is 3.49% and 3.72% in the 30-day chart. Further, Ultragenyx Pharmaceutical Inc (RARE) has a beta value of 0.55, and an average true range (ATR) of 1.71. Analysts have given the company’s stock an average 52-week price target of $90, forecast between a low of $85 and high of $95. Looking at the price targets, the low is -72.13% off current price level while to achieve the yearly target high, price needs to move -92.39%. Nonetheless, investors will most likely welcome a -82.26% jump to $90 which is the analysts’ median price.
If we refocus on Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), historical trading data shows that trading volumes averaged 0.48 over the past 10 days and 698.53K over the past 3 months. The company’s latest data on shares outstanding shows there are 92.24 million shares.
The 9.79% of Ultragenyx Pharmaceutical Inc’s shares are in the hands of company insiders while institutional holders own 92.12% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.35 million on 2024-11-15, giving us a short ratio of 4.01. The data shows that as of 2024-11-15 short interest in Ultragenyx Pharmaceutical Inc (RARE) stood at 416.0 of shares outstanding, with shares short rising to 3.16 million registered in 2024-10-15. Current price change has pushed the stock 3.26% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RARE stock continues to rise going into the next quarter.
